Characterization of Antibody-drug Conjugates

Antibody-drug conjugates (ADCs) represent a rapidly growing class of anti-cancer therapeutics in which a potent small molecule is linked to a monoclonal antibody.

To-date, two antibody-drug conjugates have been approved by regulators in the United States, Canada and Europe. These two modalities conjugate the cytotoxic drugs to either lysine or cysteine after reduction of four inter-chain disulfide bonds.

Due to the (1) small molecule property, the (1) chemical linking chemistry and (3) different amino acid conjugation, antibody-drug conjugates or ADCs exhibits a more complex and heterogeneous structure than the parent monoclonal antibody.


This complexity and heterogeneity present a significant challenge.

However, analytical characterization plays a crucial role during discovery, process scale-up, manufacturing, and release/stability testing of antibody-drug conjugates. This includes the determination of drug-to-antibody ratios (DAR) and sites of conjugation.

Hence, the selection of appropriate analytical techniques, which depends on the properties of the linker, the drug and the choice of attachment site, is critical.

This educational video addresses available solutions.

Video: Antibody Drug Conjugates (ADCs): Characterization Courtesy: © 2015 Waters Inc. Used with permission.

Previous articleTargeting Cancer with Antibody-drug Conjugates
Next articleTriphase’s TRPH-222, a Site-specific Anti-CD22 ADC, Enters Clinical Phase I Trials
ADC Review
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) launched in 2013, is designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, (basic, translational and clinical) research, clinicians/physicians, along with regulatory affairs, government authorities and representatives from payers, and policy makers. The Journal’s content includes peer reviewed research, commentaries, news features, discussions, editorials and blogs on topics relevant to a broad international readership. The Journal also offers a knowledge center (called ADC University) offering the latest and most relevant information about Antibody-drug Conjugates (ADCs), BiSpecific Antibodies, Site Specific Antibody Drug Conjugates, Small Molecule Drug Conjugates (SMDC), and Engineered Antibody Fragments. The purpose of the Journal is to present this information in an understandable and a useful format for all stakeholders.